吲哚布芬对2型糖尿病患者血小板聚集及凝血机制的影响

Effect of Indobufen on Piatelet Aggregation and Coagulation in Type 2 Diabetic Patients

【目的】观察吲哚布芬对2型糖尿病患者血小板聚集功能及凝血机制的影响。【方法】分别以比浊法和凝固法检测应用吲哚布芬治疗前后2型糖尿病患者的血小板最大聚集率（MAR）和凝血全套各指标的变化。【结果】经吲哚布芬治疗后，61例2型糖尿病患者活化部分凝血活酶时间（APTT）、纤维蛋白原凝固时间（FIBT）明显延长（P〈0．05），纤维蛋白原（FIB）浓度和由二磷酸腺苷、胶原、花生四烯酸诱导的MAR显著降低（P〈0．05），而凝血酶原时间（PT）、国际标准化比值（INR）、凝血酶时间（TT）和由凝血酶诱导的MAR无明显变化（P〉0．05）。【结论】吲哚布芬可抑制2型糖尿病患者的血小板聚集及改善其血流动力学，而对PT、TT、INR等无明显影响，是2型糖尿病患者抗血小板治疗的一种安全有效药物。

[Objective] To observe the effect of indobufen on platelet aggregation and coagulation of type 2 diabetic patients. [Methods]The changes of maximal platelet aggregation（MAR） and indices of blood coagulation were observed before and after indobufen was used for the treatment of type 2 diabetic patients by using turbidimetry and freezing method. [Results] After the treatment with indobufen, activated partial thromboplastin time（APTT） and fibrinogen clotting time（FIBT） of 61 patients with type 2 diabetes mellitus were pro- longed obviously（ P〈0.05）, while fibrinogen（FIB） and MAR induced by adenosine diphosphate（ADP）, collagen（Coil） and arachidonicacid（ACA） were decreased obviously（ P 〈0.05）. No change of prothrombin time （PT）, international normalized ratio（INR）, thrombin time（TT） and MAR induced by thrombin was found（ P 〉0.05）. [Conclusion] Indobufen can inhibit platelet aggregation and improve the hemodynamics in type 2 dia- betic patients, and has no effect on PT, TT and INR. Therefore, it is safe and effective in anti-platelet aggregation treatment of type 2 diabetic patients.